Stephens Investment Management Group LLC Acquires 64,131 Shares of Pacira Pharmaceuticals, Inc. (PCRX)

Stephens Investment Management Group LLC boosted its position in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 6.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,007,100 shares of the company’s stock after purchasing an additional 64,131 shares during the period. Stephens Investment Management Group LLC owned about 2.50% of Pacira Pharmaceuticals worth $37,817,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of the stock. Principal Financial Group Inc. lifted its stake in Pacira Pharmaceuticals by 5.2% in the 2nd quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock valued at $261,000 after purchasing an additional 270 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in Pacira Pharmaceuticals by 12.2% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after purchasing an additional 303 shares in the last quarter. Denver Investment Advisors LLC increased its stake in Pacira Pharmaceuticals by 6.8% in the second quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock valued at $327,000 after purchasing an additional 435 shares in the last quarter. Finally, Amalgamated Bank increased its stake in Pacira Pharmaceuticals by 12.7% in the second quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock valued at $240,000 after purchasing an additional 566 shares in the last quarter. Institutional investors and hedge funds own 99.79% of the company’s stock.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) traded up $0.75 during mid-day trading on Monday, reaching $40.25. The company had a trading volume of 715,900 shares, compared to its average volume of 843,788. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.81 and a 52-week high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. The company had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $0.20 earnings per share. equities analysts predict that Pacira Pharmaceuticals, Inc. will post -0.87 EPS for the current fiscal year.

A number of analysts recently commented on the stock. Jefferies Group LLC restated a “buy” rating and set a $59.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Mizuho reaffirmed a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Canaccord Genuity reiterated a “buy” rating and set a $56.00 price objective on shares of Pacira Pharmaceuticals in a research report on Monday, July 31st. Finally, BMO Capital Markets reduced their price target on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a “market perform” rating on the stock in a research report on Thursday, August 3rd. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $49.71.

In related news, Director Mark A. Kronenfeld acquired 1,000 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were bought at an average cost of $41.60 per share, with a total value of $41,600.00. Following the completion of the acquisition, the director now owns 6,795 shares of the company’s stock, valued at $282,672. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO David M. Stack sold 58,885 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total value of $2,257,650.90. Following the sale, the chief executive officer now directly owns 159,164 shares in the company, valued at $6,102,347.76. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Stephens Investment Management Group LLC Acquires 64,131 Shares of Pacira Pharmaceuticals, Inc. (PCRX)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/11/20/stephens-investment-management-group-llc-acquires-64131-shares-of-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply